Michael Flanagan

Texas filmmaker Michael Flanagan profiles 91-year-old Rio Grande-based painter Manuel Miranda.

Roche unveiled initial Phase III Krascendo 1 results in which its next-generation KRAS G12C inhibitor divarasib bested Amgen's Lumakras (sotorasib) and

Findings reported this week from separate Phase Ib trials suggest that Teva and Forte Biosciences are independently working on mAbs designed to

“Either you OD and die or you become an elder and tell stories.”– Bambi Lake

KOL Views Preview: Did Biogen, Ionis just answer or raise more questions about anti-tau diranersen in AD?

European regulators zigged where the FDA zagged by approving Sanofi's Cenrifki (tolebrutinib) to treat non-relapsing secondary progressive multiple

Tryngolza (olezarsen) was approved in June for severe hypertriglyceridaemia (HTG) but Ionis Pharmaceuticals may already be looking in the rearview

US regulators gave Celcuity the green light for Revtorpyk (gedatolisib) as second-line or later therapy for HR+, HER2- metastatic breast cancer in patients who lack a PIK3CA mutation.

Despite having already rejected Replimmune's oncolytic immunotherapy twice, the FDA reversed course — perhaps swayed by a positive adcom vote last

Takeda and Protagonist Therapeutics' rusfertide could be approved for polycythemia vera (PV) any day now , but the hepcidin mimetic looks increasingly